294 related articles for article (PubMed ID: 27183546)
1. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials.
Parrish RK; Campochiaro PA; Pearson PA; Green K; Traverso CE;
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):426-35. PubMed ID: 27183546
[TBL] [Abstract][Full Text] [Related]
2. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom.
Bailey C; Chakravarthy U; Lotery A; Menon G; Talks J;
Eye (Lond); 2017 Dec; 31(12):1707-1715. PubMed ID: 28737758
[TBL] [Abstract][Full Text] [Related]
4. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
5. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
6. Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries.
Chakravarthy U; Taylor SR; Koch FHJ; Castro de Sousa JP; Bailey C;
Br J Ophthalmol; 2019 Aug; 103(8):1072-1077. PubMed ID: 30242062
[TBL] [Abstract][Full Text] [Related]
7. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
8. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
Pearson PA; Comstock TL; Ip M; Callanan D; Morse LS; Ashton P; Levy B; Mann ES; Eliott D
Ophthalmology; 2011 Aug; 118(8):1580-7. PubMed ID: 21813090
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
10. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.
Alfaqawi F; Lip PL; Elsherbiny S; Chavan R; Mitra A; Mushtaq B
Eye (Lond); 2017 Apr; 31(4):650-656. PubMed ID: 28106887
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Assessment of Optic Nerve Changes in Patients With Diabetic Macular Edema Treated With Fluocinolone Acetonide Vitreous Implants.
Parrish RK; Traverso CE; Green K; Danis RP;
Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):418-25. PubMed ID: 27183545
[TBL] [Abstract][Full Text] [Related]
12. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.
Goldstein DA; Godfrey DG; Hall A; Callanan DG; Jaffe GJ; Pearson PA; Usner DW; Comstock TL
Arch Ophthalmol; 2007 Nov; 125(11):1478-85. PubMed ID: 17923537
[TBL] [Abstract][Full Text] [Related]
13. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
[TBL] [Abstract][Full Text] [Related]
14. Fluocinolone acetonide for the treatment of diabetic macular edema.
Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
Currie CJ; Holden SE; Berni E; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
[TBL] [Abstract][Full Text] [Related]
16. INTRAOCULAR PRESSURE IN PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH DEXAMETHASONE INTRAVITREAL IMPLANT IN THE 3-YEAR MEAD STUDY.
Maturi RK; Pollack A; Uy HS; Varano M; Gomes AM; Li XY; Cui H; Lou J; Hashad Y; Whitcup SM;
Retina; 2016 Jun; 36(6):1143-52. PubMed ID: 26871523
[TBL] [Abstract][Full Text] [Related]
17. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
18. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Chen S; Boyer D; Ruiz-Moreno J; Garretson B; Gupta A; Hariprasad SM; Bailey C; Reichel E; Soubrane G; Kapik B; Billman K; Kane FE; Green K;
Ophthalmology; 2012 Oct; 119(10):2125-32. PubMed ID: 22727177
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema.
Holden SE; Currie CJ; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):5-17. PubMed ID: 28881149
[TBL] [Abstract][Full Text] [Related]
20. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW;
Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
